BioSante Pharmaceuticals Reaches Key LibiGel(R) Safety Study Enrollment Target

Links shared publicly online about this topic.

  • 790
    total visits

BioSante Pharmaceuticals Reaches Key LibiGel(R) Safety Study Enrollment Target

medicalnewstoday.com —

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced enrollment of the 2,500th woman in the LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. This important en

View full resource at medicalnewstoday.com

Tags: Cancer, Breast Cancer, Pharma, Women's Health, Safety

  • Share

Most Recently Shared on October 19, 2010 at 7:05 pm By:

mnt_womenhealth MNT Women's Health

BioSante Pharmaceuticals Reaches Key LibiGel(R) Safety Study Enrollment Target http://mnt.to/3Lrk #womenshealth

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

Women's Health Line Women's Health Line

MNT Sexual Health MNT Sexual Health

MNT Clinical Trials MNT Clinical Trials

MNT Menopause MNT Menopause

Advertisement